What Does it Cover?
Soft tissue tumors are a broad group of neoplasms that involve the connective tissue of the body. Each year, over 13,000 people in the US are diagnosed with soft tissue sarcomas and over 5,000 people succumb to the malignancy. Because soft tissue sarcomas are very ambiguous and amorphous, many time sarcomas are classified as an uncertain type. Advances in immunohistochemistry as well as the utility of novel markers such as TFE3, TLE1, MyoD1, and MUC4 have aided pathologists in classifying these soft tissue tumors. This discussion will cover the key facts and statistics about soft tissue tumors and what role IHC plays in these difficult diagnoses.
What Will You Learn?
- The advancements in immunohistochemical methods that enhance soft tissue testing
- The pathology of soft tissue cancers
- Innovative detection biomarkers including TFE3, MyoD1, MUC4, and TLE1
- Demonstration of advanced staining on clinical samples.
Who Should Watch?
- Histotechnologists
- Pathologists
- Oncologists
- Medical Directors
- Lab Managers
- Residents/Histotech Students
- Health Care Professionals
Speaker
Jeff Gordon
Merck
OEM Sales Manager
Jeff Gordon is the OEM Sales Manager for Tissue Diagnostics. He has a Bachelor of Science in Microbiology from the University of Arkansas. In his over 17 years in the diagnostic Immunohistochemistry industry, he has served as a technical consultant managing territories covering most of the United States and Canada, as International Sales Manager, and as the Director of Sales and Marketing for Cell Marque before transitioning to OEM Sales Manager for us. His roles have involved sales, marketing, customer care/complaint handling, and product development. He has given over 60 IHC-related workshops and webinars at a local, state, national, and international level.
Protein biology
- Immunohistochemistry
Duration:1h 5min
語言:English
會話 1:提出 June 29, 2019
若要繼續閱讀，請登入或建立帳戶。
還沒有帳戶？